stockrow
Friday 6 November 2026
Export BBNX’s income statement to Excel — free account
Beta Bionics, Inc.
BBNX Healthcare Medical Devices
Beta Bionics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $100.3 million, up 53.9% from fiscal 2024.
- Revenue
- +30.3%
- EPS
- −58.6%
- Free cash flow
- −45.5%
Quarter to September 2026, against a year earlier
15.72
0.23
+1.48%
Follow BBNX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
12.32 | 4.04 | 5.87 | 6.94 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(143.15) | (18.68) | (47.74) | (71.89) | |
P/B ratio |
4.29 | 1.64 | 2.72 | 2.20 | |
Price to Tangible BV |
4.29 | 1.64 | 2.72 | 2.20 | |
EV/Sales |
10.13 | 2.23 | 4.35 | 5.05 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(19.94) | (4.48) | (9.27) | (10.83) | |
EV/FCF |
(3.05) | (0.73) | (1.53) | (1.88) | |
Quick Ratio |
7.64 | 9.29 | 7.64 | 7.95 | |
Current Ratio |
8.66 | 10.69 | 8.88 | 8.92 | |
Net Debt/EBITDA |
16.66 | 8.57 | 7.44 | 9.52 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.42 | 0.34 | 0.38 | 0.33 | |
Operating CF/Net income |
0.64 | 1.09 | 0.62 | 0.50 | |
Capex/Depreciation |
(94.01) | (1.40) | (0.80) | (1.68) | |
Research and Development Expense of Revenue |
31.54% | 37.49% | 31.99% | 33.73% | |
Selling, General and Administrative Expense of Revenue |
77.63% | 109.87% | 106.96% | 98.48% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
13.40% | 19.57% | 21.92% | 18.91% | |
Graham Net Nets |
0.18 | 0.48 | 0.28 | 0.28 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.40%) | (15.07%) | (10.53%) | (9.71%) | |
Free Cash Flow Yield |
(26.96%) | (75.88%) | (48.44%) | (38.79%) | |
Revenue per Share |
0.79 | 0.62 | 0.72 | 0.76 | |
Operating CF per Share |
(0.21) | (0.54) | (0.33) | (0.26) | |
Capex per Share |
(6.88) | (0.03) | (0.02) | (0.05) | |
Free Cash Flow per Share |
(7.09) | (0.57) | (0.35) | (0.31) | |
Cash per Share |
5.41 | 4.49 | 4.05 | 5.16 | |
Shareholders Equity per Share |
7.10 | 6.10 | 5.76 | 8.62 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.10 | 6.10 | 5.76 | 8.62 | |
Free Cash Flow |
(287.27) | (25.21) | (15.66) | (14.56) | |
Working Capital |
236.98 | 224.80 | 205.02 | 260.11 | |
Capital Expenditures |
(278.64) | (1.38) | (1.04) | (2.27) | |
Net Current Asset Value |
226.77 | 214.81 | 195.01 | 250.57 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
8.67 | 0.05 | 0.03 | 0.06 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
14.56 | 12.41 | 14.72 | 16.10 | |
Average Payables |
3.93 | 2.89 | 4.39 | 4.57 | |
Average Inventory |
17.52 | 19.73 | 20.62 | 21.67 | |
Average Assets |
239.19 | 321.22 | 311.18 | 386.90 | |
Average Common Equity |
21.13 | 292.50 | 279.00 | 348.07 |
Columns are period end dates · fundamentals updated 2 Nov 2026